Entrada Therapeutics Stock Investor Sentiment

TRDA Stock  USD 10.81  0.01  0.09%   
About 57% of Entrada Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Entrada Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Entrada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Entrada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Entrada Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Entrada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two weeks ago at zacks.com         
Entrada Therapeutics, Inc. Surpasses Q4 Earnings and Revenue Estimates
zacks News
over two weeks ago at zacks.com         
Vir Biotechnology, Inc. Reports Q4 Loss, Lags Revenue Estimates
zacks News
over two weeks ago at gurufocus.com         
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Gurufocus Stories at Macroaxis
over two weeks ago at benzinga.com         
FDA Clears Entrada Therapeutics Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
benzinga news
over three weeks ago at news.google.com         
H.C. Wainwright maintains 20 target on Entrada Therapeutics stock - MSN
Google News at Macroaxis
over three weeks ago at news.google.com         
Trading With Integrated Risk Controls - Stock Traders Daily
Google News at Macroaxis
over a month ago at gurufocus.com         
JANUS HENDERSON GROUP PLCs Strategic Acquisition in Entrada Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Entrada Therapeutics, Inc. A Cheap Biotech Stock to Invest In Now
Yahoo News
over a month ago at news.google.com         
How the price action is used to our Advantage - Stock Traders Daily
Google News at Macroaxis
over a month ago at news.google.com         
Entrada Therapeutics Buy Rating Reiterated at HC Wainwright - MarketBeat
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
HC Wainwright Reaffirms Buy Rating for Entrada Therapeutics
news
over a month ago at news.google.com         
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Google News at Macroaxis
over a month ago at gurufocus.com         
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at globenewswire.com         
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phas...
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phas...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Entrada Therapeutics that are available to investors today. That information is available publicly through Entrada media outlets and privately through word of mouth or via Entrada internal channels. However, regardless of the origin, that massive amount of Entrada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Entrada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Entrada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Entrada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Entrada Therapeutics alpha.

Entrada Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/18/2024
2
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc
02/04/2025
3
Entrada Therapeutics Buy Rating Reiterated at HC Wainwright - MarketBeat
02/07/2025
4
JANUS HENDERSON GROUP PLCs Strategic Acquisition in Entrada Therapeutics Inc
02/14/2025
5
FDA Clears Entrada Therapeutics Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
02/24/2025
6
Entrada Therapeutics, Inc. Surpasses Q4 Earnings and Revenue Estimates
02/27/2025
7
Disposition of 6138 shares by Natarajan Sethuraman of Entrada Therapeutics at 11.6786 subject to Rule 16b-3
03/03/2025
8
Acquisition by Natarajan Sethuraman of 90800 shares of Entrada Therapeutics at 11.94 subject to Rule 16b-3
03/04/2025
9
Acquisition by Kim Peter S of 2750 shares of Entrada Therapeutics at 13.6397 subject to Rule 16b-3
03/05/2025
10
Disposition of 638 shares by Natarajan Sethuraman of Entrada Therapeutics at 18.0 subject to Rule 16b-3
03/10/2025
11
Disposition of 171 shares by Nathan Dowden of Entrada Therapeutics at 15.126 subject to Rule 16b-3
03/14/2025

Complementary Tools for Entrada Stock analysis

When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Global Correlations
Find global opportunities by holding instruments from different markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format